

Syndax Announces Participation at Two Upcoming Investor Conferences

February 24, 2021

WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming virtual investor conferences:

- A panel at the Cowen 41st Annual Health Care Conference at 11:40 a.m. ET on Wednesday, March 3, 2021.
- A fireside chat at the Barclays Global Healthcare Conference at 3:35 p.m. ET on Tuesday, March 9, 2021.

A live webcast of the Barclays presentation can be accessed from the Investor section of the Company's website at <u>www.syndax.com</u>, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit <u>www.syndax.com</u> or follow the Company on <u>Twitter</u> and <u>LinkedIn</u>.

Syndax Contacts

Investor Contact Melissa Forst Argot Partners melissa@argotpartners.com Tel 212.600.1902

Media Contact Ted Held ted.held@gcihealth.com Tel 212.798.9842

SNDX-G

C View original content: http://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-301234357.html

SOURCE Syndax Pharmaceuticals, Inc.